Advertisement

CNS Drugs

, Volume 32, Issue 2, pp 135–147 | Cite as

Tardive Dyskinesia Associated with Atypical Antipsychotics: Prevalence, Mechanisms and Management Strategies

  • Katharina Stegmayer
  • Sebastian Walther
  • Peter van Harten
Review Article

Abstract

All antipsychotics, including the atypical antipsychotics (AAPs), may cause tardive dyskinesia (TD), a potentially irreversible movement disorder, the pathophysiology of which is currently unknown. The prevention and treatment of TD remain major challenges for clinicians. We conducted a PubMed search to review the prevalence and etiology of and management strategies for TD associated with AAPs. TD prevalence rates varied substantially between studies, with an estimated prevalence of around 20% in patients using AAPs. The risk of TD is lower with AAPs than with typical antipsychotics (TAPs) but remains a problem because AAPs are increasingly being prescribed. Important risk factors associated with TD include the duration of antipsychotic use, age, and ethnicity other than Caucasian. Theories about the etiology of TD include supersensitivity of the dopamine receptors and oxidative stress, but other neurotransmitters and factors are probably involved. Studies concerning the management of TD have considerable methodological limitations. Thus, recommendations for the management of TD are based on a few trials and clinical experience, and no general guidelines for the management of TD can be established. The best management strategy remains prevention. Caution is required when prescribing antipsychotics, and regular screening is needed for early detection of TD. Other strategies may include reducing the AAP dosage, switching to clozapine, or administering vesicular monoamine transporter (VMAT)-2 inhibitors. In severe cases, local injections of botulinum toxin or deep brain stimulation may be considered. More clinical trials in larger samples are needed to gather valid information on the effect of interventions targeting TD.

Notes

Funding

No sources of funding were used to prepare this manuscript.

Compliance with Ethical Standards

Conflict of Interest

In the last 10 years, Sebastian Walther has received honoraria for serving as a speaker in educational programs from Eli Lilly, Janssen, Lundbeck, and Otsuka. He was an advisory board member for Lundbeck and Otsuka from 2015 to 2016. Katharina Stegmayer and Peter van Harten have no conflicts of interest.

Supplementary material

40263_2018_494_MOESM1_ESM.docx (13 kb)
Supplementary material 1 (DOCX 13 kb)

References

  1. 1.
    Walther S, Strik W. Motor symptoms and schizophrenia. Neuropsychobiology. 2012;66(2):77–92.  https://doi.org/10.1159/000339456.CrossRefPubMedGoogle Scholar
  2. 2.
    Aquino CC, Lang AE. Tardive dyskinesia syndromes: current concepts. Parkinsonism Relat Disord. 2014;20(Suppl 1):S113–7.  https://doi.org/10.1016/S1353-8020(13)70028-2.CrossRefPubMedGoogle Scholar
  3. 3.
    Peralta V, Cuesta MJ. Neuromotor abnormalities in neuroleptic-naive psychotic patients: antecedents, clinical correlates, and prediction of treatment response. Compr Psychiatry. 2011;52(2):139–45.  https://doi.org/10.1016/j.comppsych.2010.05.009.CrossRefPubMedGoogle Scholar
  4. 4.
    Peralta V, Campos MS, De Jalon EG, Cuesta MJ. Motor behavior abnormalities in drug-naive patients with schizophrenia spectrum disorders. Mov Disord. 2010;25(8):1068–76.  https://doi.org/10.1002/mds.23050.CrossRefPubMedGoogle Scholar
  5. 5.
    Peralta V, Cuesta MJ. The effect of antipsychotic medication on neuromotor abnormalities in neuroleptic-naive nonaffective psychotic patients: a naturalistic study with haloperidol, risperidone, or olanzapine. Prim Care Companion J Clin Psychiatry. 2010.  https://doi.org/10.4088/pcc.09m00799gry.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Kindler J, Schultze-Lutter F, Michel C, Martz-Irngartinger A, Linder C, Schmidt SJ, et al. Abnormal involuntary movements are linked to psychosis-risk in children and adolescents: results of a population-based study. Schizophr Res. 2016.  https://doi.org/10.1016/j.schres.2016.04.032.PubMedGoogle Scholar
  7. 7.
    Walther S, Stegmayer K, Horn H, Rampa L, Razavi N, Muller TJ, et al. The longitudinal course of gross motor activity in schizophrenia—within and between episodes. Front Psychiatry. 2015;6:10.  https://doi.org/10.3389/fpsyt.2015.00010.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Walther S, Stegmayer K, Horn H, Razavi N, Muller TJ, Strik W. Physical activity in schizophrenia is higher in the first episode than in subsequent ones. Front Psychiatry. 2014;5:191.  https://doi.org/10.3389/fpsyt.2014.00191.PubMedGoogle Scholar
  9. 9.
    van Harten PN, Walther S, Kent JS, Sponheim SR, Mittal VA. The clinical and prognostic value of motor abnormalities in psychosis, and the importance of instrumental assessment. Neurosci Biobehav Rev. 2017;80:476–87.  https://doi.org/10.1016/j.neubiorev.2017.06.007.CrossRefPubMedGoogle Scholar
  10. 10.
    Peralta V, Cuesta MJ. Motor abnormalities: from neurodevelopmental to neurodegenerative through “functional” (neuro) psychiatric disorders. Schizophr Bull. 2017;43(5):956–71.  https://doi.org/10.1093/schbul/sbx089.CrossRefPubMedGoogle Scholar
  11. 11.
    Cornett EM, Novitch M, Kaye AD, Kata V, Kaye AM. Medication-induced tardive dyskinesia: a review and update. Ochsner J. 2017;17(2):162–74.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Ayd FJ Jr. A survey of drug-induced extrapyramidal reactions. JAMA. 1961;175:1054–60.CrossRefPubMedGoogle Scholar
  13. 13.
    Meltzer HY, Matsubara S, Lee JC. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull. 1989;25(3):390–2.PubMedGoogle Scholar
  14. 14.
    Markowitz JS, Brown CS, Moore TR. Atypical antipsychotics. Part I: pharmacology, pharmacokinetics, and efficacy. Ann Pharmacother. 1999;33(1):73–85.  https://doi.org/10.1345/aph.17215.CrossRefPubMedGoogle Scholar
  15. 15.
    Farah A. Atypicality of atypical antipsychotics. Prim Care Companion J Clin Psychiatry. 2005;7(6):268–74.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Seeberger LC, Hauser RA. Valbenazine for the treatment of tardive dyskinesia. Expert Opin Pharmacother. 2017;18(12):1279–87.  https://doi.org/10.1080/14656566.2017.1353078.CrossRefPubMedGoogle Scholar
  17. 17.
    Remington G. Tardive dyskinesia: eliminated, forgotten, or overshadowed? Curr Opin Psychiatry. 2007;20(2):131–7.  https://doi.org/10.1097/YCO.0b013e328017f6b1.CrossRefPubMedGoogle Scholar
  18. 18.
    Doepp S, Buddeberg C. Extrapyramidal symptoms following clozapine therapy. Case report. Der Nervenarzt. 1975;46(10):589–90.PubMedGoogle Scholar
  19. 19.
    Das S, Purushothaman ST, Rajan V, Chatterjee SS, Kartha A. Clozapine-induced tardive dyskinesia. Indian J Psychol Med. 2017;39(4):551–2.  https://doi.org/10.4103/IJPSYM.IJPSYM_194_17.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Li CR, Chung YC, Park TW, Yang JC, Kim KW, Lee KH, et al. Clozapine-induced tardive dyskinesia in schizophrenic patients taking clozapine as a first-line antipsychotic drug. World J Biol Psychiatry. 2009;10(4 Pt 3):919–24.  https://doi.org/10.1080/15622970802481895.CrossRefPubMedGoogle Scholar
  21. 21.
    Mendhekar DN, Andrade C. Prochlorperazine-induced tardive dystonia and its worsening with clozapine in a non-mentally ill patient with migraine. Ann Pharmacother. 2011;45(4):545–6.  https://doi.org/10.1345/aph.1P194.CrossRefPubMedGoogle Scholar
  22. 22.
    Uzun O, Doruk A. Tardive oculogyric crisis during treatment with clozapine: report of three cases. Clin Drug Invest. 2007;27(12):861–4.CrossRefGoogle Scholar
  23. 23.
    Raguraman J, Vijaysagar J. Worsening of tardive dyskinesia due to clozapine therapy. J Postgrad Med. 2007;53(3):218.  https://doi.org/10.4103/0022-3859.33874.CrossRefPubMedGoogle Scholar
  24. 24.
    Hung TH, Lee Y, Chang YY, Chong MY, Lin PY. Reversible pisa syndrome induced by clozapine: a case report. Clin Neuropharmacol. 2007;30(6):370–2.  https://doi.org/10.1097/WNF.0b013e31805930e3.CrossRefPubMedGoogle Scholar
  25. 25.
    Lin CC, Bai YM, Chen JY, Wang YC, Liou YJ. Treatment of clozapine-associated tardive dyskinesia. Prog Neuro-Psychopharmacol Biol Psychiatry. 2008;32(2):599–600.  https://doi.org/10.1016/j.pnpbp.2007.09.009.CrossRefGoogle Scholar
  26. 26.
    Bruscas MJ, Gonzalez F, Santos JL, Sanchez E. Tardive dyskinesia associated with clozapine treatment. Prog Neuro-Psychopharmacol Biol Psychiatry. 2007;31(4):963–4.  https://doi.org/10.1016/j.pnpbp.2007.01.016.CrossRefGoogle Scholar
  27. 27.
    Mendhekar DN, Duggal HS. Clozapine-induced tardive dyskinesia and hypothyroidism. J Neuropsychiatry Clin Neurosci. 2006;18(2):245–6.  https://doi.org/10.1176/jnp.2006.18.2.245.CrossRefPubMedGoogle Scholar
  28. 28.
    Ertugrul A, Demir B. Clozapine-induced tardive dyskinesia: a case report. Prog Neuro-Psychopharmacol Biol Psychiatry. 2005;29(4):633–5.  https://doi.org/10.1016/j.pnpbp.2005.01.014.CrossRefGoogle Scholar
  29. 29.
    Miller DD. Clozapine and tardive dyskinesia. Am J Psychiatry. 2003;160(3):588.  https://doi.org/10.1176/appi.ajp.160.3.588.CrossRefPubMedGoogle Scholar
  30. 30.
    Molho ES, Factor SA. Possible tardive dystonia resulting from clozapine therapy. Mov Disord. 1999;14(5):873–4.CrossRefPubMedGoogle Scholar
  31. 31.
    Bruneau MA, Stip E. Metronome or alternating pisa syndrome: a form of tardive dystonia under clozapine treatment. Int Clin Psychopharmacol. 1998;13(5):229–32.CrossRefPubMedGoogle Scholar
  32. 32.
    Peacock L, Solgaard T, Lublin H, Gerlach J. Clozapine versus typical antipsychotics. A retro- and prospective study of extrapyramidal side effects. Psychopharmacology. 1996;124(1–2):188–96.CrossRefPubMedGoogle Scholar
  33. 33.
    de Leon J, Moral L, Camunas C. Clozapine and jaw dyskinesia: a case report. J Clin Psychiatry. 1991;52(12):494–5.PubMedGoogle Scholar
  34. 34.
    Wirshing WC, Phelan CK, van Putten T, Marder SR, Engel J. Effects of clozapine on treatment-resistant akathisia and concomitant tardive dyskinesia. J Clin Psychopharmacol. 1990;10(5):371–3.CrossRefPubMedGoogle Scholar
  35. 35.
    Casey DE. Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology. 1989;99(Suppl):S47–53.CrossRefPubMedGoogle Scholar
  36. 36.
    Kane JM, Woerner MG, Pollack S, Safferman AZ, Lieberman JA. Does clozapine cause tardive-dyskinesia. J Clin Psychiatry. 1993;54(9):327–30.PubMedGoogle Scholar
  37. 37.
    Dave M. Clozapine-related tardive-dyskinesia. Biol Psychiatry. 1994;35(11):886–7.  https://doi.org/10.1016/0006-3223(94)90025-6.CrossRefPubMedGoogle Scholar
  38. 38.
    Hazari N, Kate N, Grover S. Clozapine and tardive movement disorders: a review. Asian J Psychiatry. 2013;6(6):439–51.  https://doi.org/10.1016/j.ajp.2013.08.067.CrossRefGoogle Scholar
  39. 39.
    Meyer JM. Forgotten but not gone: new developments in the understanding and treatment of tardive dyskinesia. CNS Spectr. 2016;21(S1):13–24.  https://doi.org/10.1017/S1092852916000730.CrossRefPubMedGoogle Scholar
  40. 40.
    Tenback DE, van Harten PN. Epidemiology and risk factors for (tardive) dyskinesia. Int Rev Neurobiol. 2011;98:211–30.  https://doi.org/10.1016/B978-0-12-381328-2.00009-2.CrossRefPubMedGoogle Scholar
  41. 41.
    Rakesh G, Muzyk A, Szabo ST, Gupta S, Pae CU, Masand P. Tardive dyskinesia: 21st century may bring new treatments to a forgotten disorder. Ann Clin Psychiatry. 2017;29(2):108–19.PubMedGoogle Scholar
  42. 42.
    Fujimaki K, Morinobu S, Yamashita H, Takahashi T, Yamawaki S. Predictors of quality of life in inpatients with schizophrenia. Psychiatry Res. 2012;197(3):199–205.  https://doi.org/10.1016/j.psychres.2011.10.023.CrossRefPubMedGoogle Scholar
  43. 43.
    Cuesta MJ, Garcia de Jalon E, Campos MS, Moreno-Izco L, Lorente-Omenaca R, Sanchez-Torres AM, et al. Motor abnormalities in first-episode psychosis patients and long-term psychosocial functioning. Schizophr Res. 2017.  https://doi.org/10.1016/j.schres.2017.08.050.Google Scholar
  44. 44.
    Carbon M, Hsieh CH, Kane JM, Correll CU. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiat. 2017;78(3):E264–78.  https://doi.org/10.4088/Jcp.16r10832.CrossRefGoogle Scholar
  45. 45.
    Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry. 2008;21(2):151–6.  https://doi.org/10.1097/YCO.0b013e3282f53132.CrossRefPubMedGoogle Scholar
  46. 46.
    Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161(3):414–25.  https://doi.org/10.1176/appi.ajp.161.3.414.CrossRefPubMedGoogle Scholar
  47. 47.
    Miller DD, Caroff SN, Davis SM, Rosenheck RA, McEvoy JP, Saltz BL, et al. Extrapyramidal side-effects of antipsychotics in a randomised trial. Brit J Psychiatry. 2008;193(4):279–88.  https://doi.org/10.1192/bjp.bp.108.050088.CrossRefGoogle Scholar
  48. 48.
    de Leon J. The effect of atypical versus typical antipsychotics on tardive dyskinesia—a naturalistic study. Eur Arch Psy Clin N. 2007;257(3):169–72.  https://doi.org/10.1007/s00406-006-0705-z.CrossRefGoogle Scholar
  49. 49.
    Mentzel TQ, Lieverse R, Bloemen O, Viechtbauer W, van Harten PN, Genetic R, et al. High incidence and prevalence of drug-related movement disorders in young patients with psychotic disorders. J Clin Psychopharmacol. 2017;37(2):231–8.  https://doi.org/10.1097/JCP.0000000000000666.CrossRefPubMedGoogle Scholar
  50. 50.
    Parksepp M, Ljubajev U, Taht K, Janno S. Prevalence of neuroleptic-induced movement disorders: an 8-year follow-up study in chronic schizophrenia inpatients. Nordic J Psychiatry. 2016;70(7):498–502.  https://doi.org/10.3109/08039488.2016.1164245.CrossRefGoogle Scholar
  51. 51.
    Nakata Y, Kanahara N, Kimura H, Watanabe H, Iyo M. Efficacy of clozapine on dopamine supersensitivity psychosis in schizophrenia. Int Clin Psychopharmacol. 2017;32(3):169–73.  https://doi.org/10.1097/YIC.0000000000000160.CrossRefPubMedGoogle Scholar
  52. 52.
    O’Brien A. Comparing the risk of tardive dyskinesia in older adults with first-generation and second-generation antipsychotics: a systematic review and meta-analysis. Int J Geriatr Psychiatry. 2016;31(7):683–93.  https://doi.org/10.1002/gps.4399.CrossRefPubMedGoogle Scholar
  53. 53.
    Dean CE, Kuskowski MA, Caligiuri MP. Predictors of neuroleptic-induced dyskinesia and parkinsonism: the influence of measurement methods and definitions. J Clin Psychopharmacol. 2006;26(6):560–5.  https://doi.org/10.1097/01.jcp.0000245559.14284.e3.CrossRefPubMedGoogle Scholar
  54. 54.
    Tenback DE, van Harten PN, Slooff CJ, van Os J. Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European schizophrenia outpatient health outcomes (SOHO) study. Am J Psychiat. 2006;163(8):1438–40.  https://doi.org/10.1176/appi.ajp.163.8.1438.CrossRefPubMedGoogle Scholar
  55. 55.
    Klawans HL Jr, Rubovits R. An experimental model of tardive dyskinesia. J Neural Transm. 1972;33(3):235–46.CrossRefPubMedGoogle Scholar
  56. 56.
    Tarsy D, Baldessarini RJ. Pharmacologically induced behavioural supersensitivity to apomorphine. Nature. 1973;245(148):262–3.Google Scholar
  57. 57.
    Cloud LJ, Zutshi D, Factor SA. Tardive dyskinesia: therapeutic options for an increasingly common disorder. Neurotherapeutics. 2014;11(1):166–76.  https://doi.org/10.1007/s13311-013-0222-5.CrossRefPubMedGoogle Scholar
  58. 58.
    Casey DE. Pathophysiology of antipsychotic drug-induced movement disorders. J Clin Psychiatry. 2004;65(Suppl 9):25–8.PubMedGoogle Scholar
  59. 59.
    Waddington JL, Cross AJ, Gamble SJ, Bourne RC. Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment. Science. 1983;220(4596):530–2.CrossRefPubMedGoogle Scholar
  60. 60.
    Crow TJ, Cross AJ, Johnstone EC, Owen F, Owens DGC, Waddington JL. Abnormal involuntary movements in schizophrenia—are they related to the disease process or its treatment—are they associated with changes in dopamine-receptors. J Clin Psychopharmacol. 1982;2(5):336–40.CrossRefPubMedGoogle Scholar
  61. 61.
    Casey DE. Tardive dyskinesia: pathophysiology and animal models. J Clin Psychiatry. 2000;61(Suppl 4):5–9.PubMedGoogle Scholar
  62. 62.
    Casey DE, Gerlach J, Magelund G, Christensen TR. gamma-Acetylenic GABA in tardive dyskinesia. Arch Gen Psychiatry. 1980;37(12):1376–9.CrossRefPubMedGoogle Scholar
  63. 63.
    Gunne LM, Haggstrom JE, Sjoquist B. Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis. Nature. 1984;309(5966):347–9.CrossRefPubMedGoogle Scholar
  64. 64.
    Thaker GK, Tamminga CA, Alphs LD, Lafferman J, Ferraro TN, Hare TA. Brain gamma-aminobutyric acid abnormality in tardive dyskinesia. Reduction in cerebrospinal fluid GABA levels and therapeutic response to GABA agonist treatment. Arch Gen Psychiatry. 1987;44(6):522–9.CrossRefPubMedGoogle Scholar
  65. 65.
    Perry TL, Hansen S, Jones K. Schizophrenia, tardive dyskinesia, and brain GABA. Biol Psychiat. 1989;25(2):200–6.CrossRefPubMedGoogle Scholar
  66. 66.
    Levesque C, Hernandez G, Mahmoudi S, Calon F, Gasparini F, Gomez-Mancilla B, et al. Deficient striatal adaptation in aminergic and glutamatergic neurotransmission is associated with tardive dyskinesia in non-human primates exposed to antipsychotic drugs. Neuroscience. 2017;361:43–57.  https://doi.org/10.1016/j.neuroscience.2017.07.068.CrossRefPubMedGoogle Scholar
  67. 67.
    Mahadik SP, Laev H, Korenovsky A, Karpiak SE. Haloperidol alters rat CNS cholinergic system: enzymatic and morphological analyses. Biol Psychiat. 1988;24(2):199–217.CrossRefPubMedGoogle Scholar
  68. 68.
    Blanchet PJ, Parent MT, Rompre PH, Levesque D. Relevance of animal models to human tardive dyskinesia. Behavioral and brain functions : BBF. 2012;8:12.  https://doi.org/10.1186/1744-9081-8-12.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Muller DJ, Schulze TG, Knapp M, Held T, Krauss H, Weber T, et al. Familial occurrence of tardive dyskinesia. Acta Psychiatr Scand. 2001;104(5):375–9.CrossRefPubMedGoogle Scholar
  70. 70.
    Weinhold P, Wegner JT, Kane JM. Familial occurrence of tardive dyskinesia. J Clin Psychiatry. 1981;42(4):165–6.PubMedGoogle Scholar
  71. 71.
    Yassa R, Ananth J. Familial tardive dyskinesia. Am J Psychiatry. 1981;138(12):1618–9.  https://doi.org/10.1176/ajp.138.12.1618.CrossRefPubMedGoogle Scholar
  72. 72.
    Youssef H, Lyster G, Youssef F. Familial psychosis and vulnerability to tardive dyskinesia. Int Clin Psychopharmacol. 1989;4(4):323–8.CrossRefPubMedGoogle Scholar
  73. 73.
    MacNeil RR, Muller DJ. Genetics of common antipsychotic-induced adverse effects. Mol Neuropsychiatry. 2016;2(2):61–78.  https://doi.org/10.1159/000445802.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Tsai G, Goff DC, Chang RW, Flood J, Baer L, Coyle JT. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am J Psychiatry. 1998;155(9):1207–13.  https://doi.org/10.1176/ajp.155.9.1207.CrossRefPubMedGoogle Scholar
  75. 75.
    Walther S, Schappi L, Federspiel A, Bohlhalter S, Wiest R, Strik W, et al. Resting-state hyperperfusion of the supplementary motor area in catatonia. Schizophr Bull. 2016.  https://doi.org/10.1093/schbul/sbw140.Google Scholar
  76. 76.
    Walther S. Psychomotor symptoms of schizophrenia map on the cerebral motor circuit. Psychiatry Res. 2015;233(3):293–8.  https://doi.org/10.1016/j.pscychresns.2015.06.010.CrossRefPubMedGoogle Scholar
  77. 77.
    Stegmayer K, Horn H, Federspiel A, Razavi N, Bracht T, Laimbock K, et al. Supplementary motor area (SMA) volume is associated with psychotic aberrant motor behaviour of patients with schizophrenia. Psychiatry Res. 2014;223(1):49–51.  https://doi.org/10.1016/j.pscychresns.2014.05.002.CrossRefPubMedGoogle Scholar
  78. 78.
    Walther S, Stegmayer K, Federspiel A, Bohlhalter S, Wiest R, Viher PV. Aberrant hyperconnectivity in the motor system at rest is linked to motor abnormalities in schizophrenia spectrum disorders. Schizophr Bull. 2017;43(5):982–92.  https://doi.org/10.1093/schbul/sbx091.CrossRefPubMedGoogle Scholar
  79. 79.
    Hirjak D, Wolf RC, Wilder-Smith EP, Kubera KM, Thomann PA. Motor abnormalities and basal ganglia in schizophrenia: evidence from structural magnetic resonance imaging. Brain Topogr. 2015;28(1):135–52.  https://doi.org/10.1007/s10548-014-0377-3.CrossRefPubMedGoogle Scholar
  80. 80.
    Schroder J, Wenz F, Schad LR, Baudendistel K, Knopp MV. Sensorimotor cortex and supplementary motor area changes in schizophrenia. A study with functional magnetic resonance imaging. Br J Psychiatry. 1995;167(2):197–201.CrossRefPubMedGoogle Scholar
  81. 81.
    Martino M, Magioncalda P, Yu H, Li X, Wang Q, Meng Y, et al. Abnormal resting-state connectivity in a substantia nigra-related striato-thalamo-cortical network in a large sample of first-episode drug-naive patients with schizophrenia. Schizophr Bull. 2017.  https://doi.org/10.1093/schbul/sbx067.Google Scholar
  82. 82.
    Bai YM, Chou KH, Lin CP, Chen IY, Li CT, Yang KC, et al. White matter abnormalities in schizophrenia patients with tardive dyskinesia: a diffusion tensor image study. Schizophr Res. 2009;109(1–3):167–81.  https://doi.org/10.1016/j.schres.2009.02.003.CrossRefPubMedGoogle Scholar
  83. 83.
    Macpherson R, Collis R. Tardive dyskinesia. Patients’ lack of awareness of movement disorder. Br J Psychiatry. 1992;160:110–2.CrossRefPubMedGoogle Scholar
  84. 84.
    Caroff SN, Campbell EC, Carroll B. Pharmacological treatment of tardive dyskinesia: recent developments. Expert Rev Neurother. 2017;17(9):871–81.  https://doi.org/10.1080/14737175.2017.1358616.CrossRefPubMedGoogle Scholar
  85. 85.
    Koning JP, Tenback DE, Kahn RS, Van Schelven LJ, Van Harten PN. Instrument measurement of lingual force variability reflects tardive tongue dyskinesia. J Med Eng Technol. 2010;34(1):71–7.  https://doi.org/10.3109/03091900903402105.CrossRefPubMedGoogle Scholar
  86. 86.
    Koshino Y, Wada Y, Isaki K, Kurata K. A long-term outcome study of tardive dyskinesia in patients on antipsychotic medication. Clin Neuropharmacol. 1991;14(6):537–46.CrossRefPubMedGoogle Scholar
  87. 87.
    Gardos G, Cole JO, Perenyi A, Casey DE, Samu I, Kallos M, et al. Five-year follow-up study of tardive dyskinesia. Adv Biochem Psychopharmacol. 1985;40:37–42.PubMedGoogle Scholar
  88. 88.
    Soares-Weiser K, Rathbone J. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. Cochrane Databse Syst Rev. 2006;1:CD000459 (Artn Cd00045910.1002/14651858.Cd000459.Pub2).Google Scholar
  89. 89.
    Glazer WM, Hafez HM, Benarroche CL. Molindone and haloperidol in tardive dyskinesia. J Clin Psychiatry. 1985;46(8 Pt 2):4–7.PubMedGoogle Scholar
  90. 90.
    Kazamatsuri H, Chien C, Cole JO. Treatment of tardive dyskinesia. II. Short-term efficacy of dopamine-blocking agents haloperidol and thiopropazate. Arch Gen Psychiatry. 1972;27(1):100–3.CrossRefPubMedGoogle Scholar
  91. 91.
    Mentzel CL, Bakker PR, van Os J, Drukker M, Matroos GE, Hoek HW, et al. Effect of antipsychotic type and dose changes on tardive dyskinesia and parkinsonism severity in patients with a serious mental illness: the curacao extrapyramidal syndromes study XII. J Clin Psychiatry. 2017;78(3):e279–85.  https://doi.org/10.4088/JCP.16m11049.CrossRefPubMedGoogle Scholar
  92. 92.
    Bai YM, Yu SC, Chen JY, Lin CY, Chou P, Lin CC. Risperidone for pre-existing severe tardive dyskinesia: a 48-week prospective follow-up study. Int Clin Psychopharm. 2005;20(2):79–85.  https://doi.org/10.1097/00004850-200503000-00003.CrossRefGoogle Scholar
  93. 93.
    Chan HY, Chiang SC, Chang CJ, Gau SS, Chen JJ, Chen CH, et al. A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia. J Clin Psychiatry. 2010;71(9):1226–33.CrossRefPubMedGoogle Scholar
  94. 94.
    Ono S, Suzuki Y, Shindo M, Endo T, Fukui N, Sugai T, et al. Improvement of tardive dyskinesia and dystonia associated with aripiprazole following a switch to quetiapine: case report and review of the literature. J Clin Pharm Ther. 2012;37(3):370–2.  https://doi.org/10.1111/j.1365-2710.2011.01290.x.CrossRefPubMedGoogle Scholar
  95. 95.
    Louza MR, Bassitt DP. Maintenance treatment of severe tardive dyskinesia with clozapine: 5 years’ follow-up. J Clin Psychopharmacol. 2005;25(2):180–2 (00004714-200504000-00012 [pii]).CrossRefPubMedGoogle Scholar
  96. 96.
    Spivak B, Mester R, Abesgaus J, Wittenberg N, Adlersberg S, Gonen N, et al. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients. J Clin Psychiatry. 1997;58(7):318–22.CrossRefPubMedGoogle Scholar
  97. 97.
    Moore NC, Lewitt PA, Gershon S. Reduction of dyskinesias and psychiatric disability with clozapine over different time courses. J Psychopharmacol. 1992;6(4):514–8.  https://doi.org/10.1177/026988119200600407.CrossRefPubMedGoogle Scholar
  98. 98.
    Bergman H, Walker DM, Nikolakopoulou A, Soares-Weiser K, Adams CE. Systematic review of interventions for treating or preventing antipsychotic-induced tardive dyskinesia. Health Technol Assess. 2017;21(43):1–218.  https://doi.org/10.3310/hta21430.CrossRefPubMedPubMedCentralGoogle Scholar
  99. 99.
    Kane JM, Rifkin A, Woerner M, Reardon G, Sarantakos S, Schiebel D, et al. Low-dose neuroleptic treatment of outpatient schizophrenics. 1. preliminary-results for relapse rates. Arch Gen Psychiatry. 1983;40(8):893–6.CrossRefPubMedGoogle Scholar
  100. 100.
    Cookson IB. The effects of a 50-percent reduction of cis(z)-flupentixol decanoate in chronic-schizophrenic patients maintained on a high-dose regime. Int Clin Psychopharm. 1987;2(2):141–9.  https://doi.org/10.1097/00004850-198704000-00008.CrossRefGoogle Scholar
  101. 101.
    Casey DE, Toenniessen LM. Neuroleptic treatment in tardive dyskinesia: can it be developed into a clinical strategy for long-term treatment? Mod Probl Pharmacopsychiatry. 1983;21:65–79.CrossRefPubMedGoogle Scholar
  102. 102.
    Yassa R, Nair NP. A 10-year follow-up study of tardive dyskinesia. Acta Psychiatr Scand. 1992;86(4):262–6.CrossRefPubMedGoogle Scholar
  103. 103.
    Yassa R, Nair V, Schwartz G. Tardive dyskinesia: a two-year follow-up study. Psychosomatics. 1984;25(11):852–5.  https://doi.org/10.1016/S0033-3182(84)72946-X.CrossRefPubMedGoogle Scholar
  104. 104.
    Yagi G, Itoh H. A 10-year follow-up study of tardive dyskinesia–with special reference to the influence of neuroleptic administration on the long-term prognosis. Keio J Med. 1985;34(4):211–9.CrossRefPubMedGoogle Scholar
  105. 105.
    Bai YM, Yu SC, Lin CC. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2003;64(11):1342–8.CrossRefPubMedGoogle Scholar
  106. 106.
    Chouinard G. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J Clin Psychopharmacol. 1995;15(1 Suppl 1):36S–44S.CrossRefPubMedGoogle Scholar
  107. 107.
    Tamminga CA, Thaker GK, Moran M, Kakigi T, Gao XM. Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry. 1994;55(Suppl B):102–6.PubMedGoogle Scholar
  108. 108.
    Emsley R, Turner HJ, Schronen J, Botha K, Smit R, Oosthuizen PP. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J Clin Psychiatry. 2004;65(5):696–701.CrossRefPubMedGoogle Scholar
  109. 109.
    Caroff SN, Davis VG, Miller DD, Davis SM, Rosenheck RA, McEvoy JP, et al. Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. J Clin Psychiatry. 2011;72(3):295–303.  https://doi.org/10.4088/JCP.09m05793yel.CrossRefPubMedGoogle Scholar
  110. 110.
    Emsley R, Turner J, Schronen J, Botha K, Smit R, Oosthuizen P. Quetiapine shows greater improvements in tardive dyskinesia compared with haloperidol. European Psychiatry. 2004;19:178s–9s.Google Scholar
  111. 111.
    Miller DD, McEvoy JP, Davis SM, Caroff SN, Saltz BL, Chakos MH, et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res. 2005;80(1):33–43.  https://doi.org/10.1016/j.schres.2005.07.034.CrossRefPubMedGoogle Scholar
  112. 112.
    Tarsy D, Lungu C, Baldessarini RJ. Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. Handbook Clin Neurol. 2011;100:601–16.  https://doi.org/10.1016/B978-0-444-52014-2.00043-4.CrossRefGoogle Scholar
  113. 113.
    Caykoylu A, Ekinci O, Yilmaz E. Resolution of risperidone-induced tardive dyskinesia with a switch to aripiprazole monotherapy. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(3):571–2.  https://doi.org/10.1016/j.pnpbp.2009.01.009.CrossRefPubMedGoogle Scholar
  114. 114.
    Schwartz T, Raza S. Aripiprazole (abilify) and tardive dyskinesia. P T. 2008;33(1):32–4.PubMedPubMedCentralGoogle Scholar
  115. 115.
    Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy long-term follow-up of a 2-year randomized clinical trial. Jama Psychiat. 2013;70(9):913–20.  https://doi.org/10.1001/jamapsychiatry.2013.19.CrossRefGoogle Scholar
  116. 116.
    Alabed S, Latifeh Y, Mohammad HA, Rifai A. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2011;4:000203.  https://doi.org/10.1002/14651858.cd000203.pub3.Google Scholar
  117. 117.
    Bhoopathi PS, Soares-Weiser K. Benzodiazepines for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2006;3:CD000205.  https://doi.org/10.1002/14651858.cd000205.pub2.Google Scholar
  118. 118.
    Essali A, Deirawan H, Soares-Weiser K, Adams CE. Calcium channel blockers for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2011;11:CD000206.  https://doi.org/10.1002/14651858.cd000206.pub3.Google Scholar
  119. 119.
    El-Sayeh HG, Lyra da Silva JP, Rathbone J, Soares-Weiser K. Non-neuroleptic catecholaminergic drugs for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2006;1:CD000458.  https://doi.org/10.1002/14651858.cd000458.pub2.Google Scholar
  120. 120.
    Adelufosi AO, Abayomi O, Ojo TM. Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2015;4:CD010501.  https://doi.org/10.1002/14651858.cd010501.pub2.Google Scholar
  121. 121.
    Soares-Weiser K, Maayan N, McGrath J. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2011;2:CD000209.  https://doi.org/10.1002/14651858.cd000209.pub2.Google Scholar
  122. 122.
    Weber SS, Dufresne RL, Becker RE, Mastrati P. Diazepam in tardive dyskinesia. Drug Intell Clin Pharm. 1983;17(7–8):523–7.CrossRefPubMedGoogle Scholar
  123. 123.
    Csernansky JG, Tacke U, Rusen D, Hollister LE. The effect of benzodiazepines on tardive dyskinesia symptoms. J Clin Psychopharmacol. 1988;8(2):154–5.CrossRefPubMedGoogle Scholar
  124. 124.
    Csernansky JG, Riney SJ, Lombrozo L, Overall JE, Hollister LE. Double-blind comparison of alprazolam, diazepam, and placebo for the treatment of negative schizophrenic symptoms. Arch Gen Psychiatry. 1988;45(7):655–9.CrossRefPubMedGoogle Scholar
  125. 125.
    Bobruff A, Gardos G, Tarsy D, Rapkin RM, Cole JO, Moore P. Clonazepam and phenobarbital in tardive dyskinesia. Am J Psychiatry. 1981;138(2):189–93.  https://doi.org/10.1176/ajp.138.2.189.CrossRefPubMedGoogle Scholar
  126. 126.
    Greil W, Haag H, Rossnagl G, Ruther E. Effect of anticholinergics on tardive dyskinesia. A controlled discontinuation study. Br J Psychiatry. 1984;145:304–10.CrossRefPubMedGoogle Scholar
  127. 127.
    Woods SW, Saksa JR, Baker CB, Cohen SJ, Tek C. Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2008;69(4):546–54.CrossRefPubMedGoogle Scholar
  128. 128.
    Dalby MA. Effect of tetrabenazine on extrapyramidal movement disorders. BMJ. 1969;2(5654):422–3.CrossRefPubMedPubMedCentralGoogle Scholar
  129. 129.
    MacCallum WA. Tetrabenazine for extra-pyramidal movement disorders. BMJ. 1970;1(5698):760.CrossRefPubMedPubMedCentralGoogle Scholar
  130. 130.
    Brandrup E. Tetrabenacine treatment in persisting dyskinesia caused by psychopharmaca. Am J Psychiatry. 1961;118:551–2.  https://doi.org/10.1176/ajp.118.6.551.CrossRefPubMedGoogle Scholar
  131. 131.
    Kazamatsuri H, Chien CP, Cole JO. Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine. Am J Psychiatry. 1973;130(4):479–83.PubMedGoogle Scholar
  132. 132.
    O’Brien CF, Jimenez R, Hauser RA, Factor SA, Burke J, Mandri D, et al. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study. Mov Disord. 2015;30(12):1681–7.  https://doi.org/10.1002/mds.26330.CrossRefPubMedPubMedCentralGoogle Scholar
  133. 133.
    Hauser RA, Factor SA, Marder SR, Knesevich MA, Ramirez PM, Jimenez R, et al. KINECT 3: A phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017;174(5):476–84.  https://doi.org/10.1176/appi.ajp.2017.16091037.CrossRefPubMedGoogle Scholar
  134. 134.
    Josiassen RC, Kane JM, Liang GS, Burke J, O’Brien CF. Long-term safety and tolerability of valbenazine (NBI-98854) in subjects with tardive dyskinesia and a diagnosis of schizophrenia or mood disorder. Psychopharmacol Bull. 2017;47(3):61–8.PubMedPubMedCentralGoogle Scholar
  135. 135.
    Fernandez HH, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study. Neurology. 2017;88(21):2003–10.  https://doi.org/10.1212/WNL.0000000000003960.CrossRefPubMedPubMedCentralGoogle Scholar
  136. 136.
    Anderson KE, Stamler D, Davis MD, Factor SA, Hauser RA, Isojarvi J, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. The lancet Psychiatry. 2017;4(8):595–604.  https://doi.org/10.1016/S2215-0366(17)30236-5.CrossRefPubMedGoogle Scholar
  137. 137.
    van Harten PN, Hovestadt A. Botulinum toxin as a treatment for tardive dyskinesia. Mov Disord. 2006;21(8):1276–7.CrossRefPubMedGoogle Scholar
  138. 138.
    Tschopp L, Salazar Z, Micheli F. Botulinum toxin in painful tardive dyskinesia. Clin Neuropharmacol. 2009;32(3):165–6.  https://doi.org/10.1097/WNF.0b013e31818ddbc4.CrossRefPubMedGoogle Scholar
  139. 139.
    Esper CD, Freeman A, Factor SA. Lingual protrusion dystonia: frequency, etiology and botulinum toxin therapy. Parkinsonism Relat Disord. 2010;16(7):438–41.  https://doi.org/10.1016/j.parkreldis.2010.04.007.CrossRefPubMedGoogle Scholar
  140. 140.
    Hennings JM, Krause E, Botzel K, Wetter TC. Successful treatment of tardive lingual dystonia with botulinum toxin: case report and review of the literature. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(5):1167–71.  https://doi.org/10.1016/j.pnpbp.2007.09.010.CrossRefPubMedGoogle Scholar
  141. 141.
    Slotema CW, van Harten PN, Bruggeman R, Hoek HW. Botulinum toxin in the treatment of orofacial tardive dyskinesia: a single blind study. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(2):507–9.  https://doi.org/10.1016/j.pnpbp.2007.10.004.CrossRefPubMedGoogle Scholar
  142. 142.
    Damier P, Thobois S, Witjas T, Cuny E, Derost P, Raoul S, et al. Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia. Arch Gen Psychiatry. 2007;64(2):170–6.  https://doi.org/10.1001/archpsyc.64.2.170.CrossRefPubMedGoogle Scholar
  143. 143.
    Schrader C, Peschel T, Petermeyer M, Dengler R, Hellwig D. Unilateral deep brain stimulation of the internal globus pallidus alleviates tardive dyskinesia. Mov Disord. 2004;19(5):583–5.  https://doi.org/10.1002/mds.10705.CrossRefPubMedGoogle Scholar
  144. 144.
    Zhang JG, Zhang K, Wang ZC. Deep brain stimulation in the treatment of tardive dystonia. Chin Med J. 2006;119(9):789–92.PubMedGoogle Scholar
  145. 145.
    Mentzel CL, Tenback DE, Tijssen MA, Visser-Vandewalle VE, van Harten PN. Efficacy and safety of deep brain stimulation in patients with medication-induced tardive dyskinesia and/or dystonia: a systematic review. J Clin Psychiatry. 2012;73(11):1434–8.  https://doi.org/10.4088/JCP.12r07643.CrossRefPubMedGoogle Scholar
  146. 146.
    Johnsen M, Wester K. Full remission of tardive dyskinesia following general anaesthesia. J Neurol. 2002;249(5):622–5.  https://doi.org/10.1007/s004150200073.CrossRefPubMedGoogle Scholar
  147. 147.
    Spindler MA, Galifianakis NB, Wilkinson JR, Duda JE. Globus pallidus interna deep brain stimulation for tardive dyskinesia: case report and review of the literature. Parkinsonism Relat Disord. 2013;19(2):141–7.  https://doi.org/10.1016/j.parkreldis.2012.09.016.CrossRefPubMedGoogle Scholar
  148. 148.
    Pouclet-Courtemanche H, Rouaud T, Thobois S, Nguyen JM, Brefel-Courbon C, Chereau I, et al. Long-term efficacy and tolerability of bilateral pallidal stimulation to treat tardive dyskinesia. Neurology. 2016;86(7):651–9.  https://doi.org/10.1212/WNL.0000000000002370.CrossRefPubMedGoogle Scholar
  149. 149.
    Kefalopoulou Z, Paschali A, Markaki E, Vassilakos P, Ellul J, Constantoyannis C. A double-blind study on a patient with tardive dyskinesia treated with pallidal deep brain stimulation. Acta Neurol Scand. 2009;119(4):269–73.  https://doi.org/10.1111/j.1600-0404.2008.01115.x.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.University Hospital of PsychiatryBernSwitzerland
  2. 2.Psychiatric Centre GGz Centraal, InnovaAmersfoortThe Netherlands
  3. 3.School for Mental Health and NeuroscienceMaastricht UniversityMaastrichtThe Netherlands

Personalised recommendations